A detailed history of Great Point Partners LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Great Point Partners LLC holds 2,811,955 shares of AUTL stock, worth $6.44 Million. This represents 4.72% of its overall portfolio holdings.

Number of Shares
2,811,955
Previous 3,441,667 18.3%
Holding current value
$6.44 Million
Previous $12 Million 14.78%
% of portfolio
4.72%
Previous 3.17%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.38 - $4.69 $2.13 Million - $2.95 Million
-629,712 Reduced 18.3%
2,811,955 $10.2 Million
Q2 2024

Aug 14, 2024

BUY
$3.33 - $5.68 $7.58 Million - $12.9 Million
2,275,000 Added 195.0%
3,441,667 $12 Million
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $6.29 Million - $8.51 Million
1,166,667 New
1,166,667 $7.44 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.